Successful re-introduction of recombinant human erythropoietin following antibody induced pure red cell aplasia
Open Access
- 13 July 2004
- journal article
- case report
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 19 (8) , 2137-2139
- https://doi.org/10.1093/ndt/gfh319
Abstract
Reports of pure red cell aplasia (PRCA) secondary to recombinant human erythropoietin (rHuEPO), predominantly following the administration of subcutaneous (s.c.) epoetin alfa, have increased dramatically over the past 3 years. Treatment with immunosuppressive agents has been partially successful in some patients, rendering them transfusion independent. To date there are no reports describing the re-introduction of rHuEPO.Keywords
This publication has 6 references indexed in Scilit:
- Low-dose cyclosporin therapy for recombinant erythropoietin-induced pure red-cell aplasiaNephrology Dialysis Transplantation, 2004
- Cyclosporine treatment for patients with CRF who developed pure red blood cell aplasia following EPO therapyAmerican Journal of Kidney Diseases, 2003
- Allergic Skin and Systemic Reactions in a Patient with Pure Red Cell Aplasia and Anti-Erythropoietin Antibodies Challenged with Different EpoetinsJournal of the American Society of Nephrology, 2002
- Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant ErythropoietinNew England Journal of Medicine, 2002
- Antibodies against Recombinant Human Erythropoietin in a Patient with Erythropoietin-Resistant AnemiaNew England Journal of Medicine, 1996
- Treatment of refractory pure red cell aplasia with cyclosporine A: disappearance of IgG inhibitor associated with clinical responseBritish Journal of Haematology, 1991